In the patients who have been on trametinib plus dabrafenib while on pembrolizumab, the median OS was 3

In the patients who have been on trametinib plus dabrafenib while on pembrolizumab, the median OS was 3.8?weeks (95% CI?=?2.5, 5.1). centered remaining lower lobe nodularity (yellowish arrow) on baseline check out(A) with treatment response on following follow-up imaging at 5?weeks (B) and 8?weeks (C). (PDF 256 kb) 40425_2018_378_MOESM2_ESM.pdf (257K) GUID:?436F1816-814C-497E-805D-99F7277EF374 Data Availability StatementAll data… Continue reading In the patients who have been on trametinib plus dabrafenib while on pembrolizumab, the median OS was 3